Medtronic secured CE Mark approval for its Affera Sphere‑360 pulsed‑field ablation (PFA) catheter on January 23 2026, clearing the device for commercial sale in the European Union and the European Economic Area.
The company also completed the first cases of its Horizon 360 IDE pivotal trial in the United States on January 22 2026, a critical step toward FDA approval and a key milestone in the U.S. regulatory pathway.
The Sphere‑360 is a single‑shot, rotation‑free catheter that delivers pulsed‑field energy for pulmonary vein isolation. The technology produces predictable, durable lesions while reducing procedure time and eliminating the need for device rotation, positioning it as a safer and more efficient alternative to traditional radiofrequency or cryoablation.
This regulatory success comes as Medtronic’s PFA franchise grew 71% in Q2 FY2026, driven by strong demand for Affera mapping systems and the Sphere‑360. CEO Geoffrey Martha noted that the rapid adoption of PFA technology is reshaping the electrophysiology market and giving Medtronic a competitive edge over rivals such as Abbott and Johnson & Johnson.
The CE Mark approval and U.S. trial progress reinforce Medtronic’s strategy to capture a larger share of the high‑growth electrophysiology market, where the adoption of PFA is expected to accelerate as safety and efficacy data accumulate.
With the CE Mark in place, Medtronic can begin commercial distribution in Europe while the U.S. IDE data will feed into the FDA review process, potentially accelerating market entry and revenue generation in the coming years.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.